Safety and Efficacy of MBI 226 2.5% and 5.0% Topical Acne Solutions in the Treatment of Acne

NCT00211523 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

75

Enrollment

INDUSTRY

Sponsor class

Conditions

Acne Vulgaris
Acne
Propionibacterium Acnes

Interventions

DRUG: MBI 226 Acne Solutions

Sponsor

BioWest Therapeutics Inc